Nuevolution AB (publ) annual report 2015/16 now available

Stockholm, 14 September 2016. Nuevolution AB (publ) announces that its annual
report 2015/16 now is available on the company’s home page
(www.nuevolution.com).

For more information, please contact:

Alex Haahr Gouliaev, CEO

Phone: +45 3913 0902

Email: ahg@nuevolution.com

Henrik Damkjær Simonsen, CFO

Phone: +45 3913 0947

Email: hs@nuevolution.com

Information about Nuevolution AB (publ)

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company
founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners
its discovery platform and programs with pharmaceutical and biotechnology
companies to seek future benefit of patients in need of novel medical treatment
option. Nuevolution’s internal programs are focused on therapeutically important
targets within inflammation, oncology and immuno-oncology.

This information is information that Nuevolution AB (publ) is obliged to make
public pursuant to the Securities Market Act. The information was sent for
publication on Wednesday 14 September, 16.45 (CEST).

Nuevolution AB (publ) is listed at Nasdaq First North in Stockholm, Sweden
(ticker: NUE.ST). Västra Hamnen Corporate Finance AB acts as Certified Advisor
to Nuevolution AB (publ). More information about Nuevolution can be found on:
www.nuevolution.com.